Shionogi has joined subsidiaries of Merck Group and Amgen in the equity portion of a series D round for the digital therapeutics developer.
US-based digital medicine developer Akili received $160m in series D debt and equity financing from investors including pharmaceutical companies Merck Group, Shionogi & Co and Amgen yesterday.
Investment manager Neuberger Berman led the $110m equity portion of the round, which included Polaris Partners, Mirae Asset Financial Group, New Leaf Venture Partners, Quad Investment Management, Ladera Venture Partners, Baillie Gifford and Jazz Venture Partners.
Evidity Health Capital, Omidyar Technology Ventures, Fearless Ventures, the Singaporean state-owned Temasek and private investor Dave Baszucki…
